… Lung cancer, which is a major cause of cancer-related … -cell lung cancer (SCLC) and
non-small-cell lung cancer (NSCLC). The latter group, which comprises roughly 80% of all lung …

Between 1981 and 1986, a total of 46 patients with small cell lung cancer (SCLC) achieving
a complete response by chemotherapy with or without chest irradiation were randomized …

Comparative study of survival of screenâ•’detected compared with symptomâ•’detected lung
cancer cases … 60.6% of the screen-detected lung cancer patients were from stage 0 to 11 …

… with lung cancer.'-'' We previously prepared numerous MoAb reactive … lung tumor tissue
from biopsy and cultured cell lines and selected three (5E8, 5C7, and 1F10) for additional study. …

… -grade LCNEC and SCLC patients for the comparative analysis of metastatic patterns.
Besides, some missing data for tumor size in high-grade SCLC patients weakened the statistical …

… because of the low number of patients in the EPSCC group. Although there is no comparative
study in literature, the results concerning patients with extensive EPSCC are frequently …

… -cell lung cancer (SCLC). No comparative study of these agents has been reported. This
randomized phase II study was conducted to select amrubicin or topotecan for future evaluation. …

… The main treatment modality for localized non-smallcell lung cancer (NSCLC) is surgical
resection [1, 2]. In locally confined but inoperable cancer, radiotherapy has proven efficacy [3]. …

e20581 Background: Response to anti–PD-L1/PD-1 therapy in patients with NSCLC has
been associated with tumor PD-L1 expression. Avelumab is a fully human anti‒PD-L1 IgG1 …

… analysis of patients with early-stage NSCLC lung cancer in the contemporary period supports
lobectomy as the optimal treatment … comparative effectiveness of SABR in certain patient …